Phase 2 BMT-801 clinical study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatideTopline results expected 1Q calendar year 2025General obesity, weight loss management, and ...

Cumulative net returns improved 20% for 4Q24 and were 39% for full year. Since inception through 2024-end, LCA returned a ...

Appellant is suspended director of Corporate Debtor who challenged the impugned order passed by NCLT, Jaipur (Adjudicating ...

PetVivo Board Appoints Eldred as Executive Director to Lead Company Product Commercialization and Operations MINNEAPOLIS, MN, Jan. 27, 2025 ...

PERFORMING effective risk assessments can be a difficult art to master. The very phrase—“compliance risk assessment”—can encompass a wide range of risks: anti-bribery, whistleblower retaliation, data ...

Meebook isn't as big as it once was. The company though is doing its bit to stem the slide and the recent launch of the ...